AVCN319301b (6mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.
AVCN319301b (9mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.
AVCN319301b (15mg): AVCN319301b is a standardized oral capsule containing a precise dose of Δ9-THC.
Placebo: The matched placebo is an oral capsule identical in appearance to the active study drug and contains the same non-medicinal ingredients but no Δ9-THC. It is manufactured to match the active capsules in size, color, taste, and packaging to maintain blinding for participants and study staff.
The goal of this clinical trial is to learn how a investigational medicinal product (THC) affects psychological and physical responses in healthy adults with prior cannabis use experience. The main questions it aims to answer are:
\- How do different dose levels of the investigational medicinal product (THC) influence short-term subjective and physiological responses?
Researchers will compare three dose levels of the study drug to a placebo (a look-alike substance with no active ingredient) to see how responses vary across sessions.
Participants will:
* Attend four in-person study visits, each involving a single dose of either the study drug or placebo
* Complete questionnaires about their moment-to-moment experiences
* Have their heart rate, blood pressure, and other physical measures monitored
* Undergo serial blood sampling to measure circulating biomarkers
| Facility | City | Region | Status |
|---|---|---|---|
| University of Calgary, Heritage Medical Research Building | Calgary | Alberta |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07346690 on ClinicalTrials.gov ↗ ← All trials in Canada